|
| Status |
Public on May 01, 2024 |
| Title |
The activity and safety of sintilimab on high-risk ground glass opacity lesions in multiple primary lung cancer patients |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death worldwide, of which approximately 85% are non-small cell lung cancer (NSCLC). The overall survival (OS) of patients with advanced NSCLC was significantly prolonged with immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) axis. For early-stage lung cancer, the 5-year survival rate for patients ranges from 80% in stage IA to 41% in stage IIIA, and many cases relapse after surgical resection. Currently, multiple clinical trials have manifested the encouraging efficacy of neoadjuvant immunotherapy in stage I-IIIA resectable NSCLC. However, the effect of immunotherapy in ultra early-stage NSCLC patients with micro-invasive or even pre-invasive lesions remains unclear. In this study, we aimed to evaluate the activity and safety of sintilimab on high-risk ground glass opacity lesions in multiple primary lung cancer patients.
|
| |
|
| Overall design |
The difference of exosomal RNA in early-stage lung cancer patients who responded to anti-PD-1 antibody or not.
|
| |
|
| Contributor(s) |
Liang W, Cheng B, Feng Y |
| Citation(s) |
38637495 |
| |
| Submission date |
Mar 04, 2024 |
| Last update date |
May 01, 2024 |
| Contact name |
Yi Feng |
| E-mail(s) |
doc.fengy@gmail.com
|
| Phone |
18076291855
|
| Organization name |
the First Affiliated Hospital of Guangzhou Medical University
|
| Street address |
Jingxiu Road, Panyu District
|
| City |
Guangzhou |
| State/province |
Guangdong |
| ZIP/Postal code |
511436 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (50)
|
|
| Relations |
| BioProject |
PRJNA1083453 |
Less...
More...